Allergan was a global pharmaceutical company best known as the maker of Botox, with products spanning aesthetics, eye care, immunology, and neurosciences. It made occasional direct strategic investments in startups (e.g., Stemson Therapeutics seed round) before being acquired by AbbVie in May 2020.
56% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $37.4M (across 8 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Seed
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Nucleus | Series B | $14M | Jul 2022 |
| Nucleus | Seed | $3.5M | Dec 2021 |
| SStemson Therapeutics | Seed | $7.5M | Sep 2020 |
| SStemson Therapeutics | Seed | — | Jan 2020 |
 Ribometrix | Series A | $30M | Nov 2018 |
 Morphic Therapeutic | Series B | $80M | Sep 2018 |
 Effector Therapeutics | Series B | $40M | Dec 2015 |
| VVitae Pharmaceuticals | Unknown | $34M | Jan 2005 |
 Syndeio Biosciences | Unknown | $90M | — |
Top Co-Investors
Seven Seven Six2 shared
Pendulum Holdings2 shared
Founders Fund2 shared
Formus Capital2 shared
Pareto Holdings1 shared
Bluewatch Ventures1 shared
Night Media1 shared
Quiet Capital1 shared
Z Fellows1 shared
SALT Fund1 shared
Shrug Capital1 shared
Arthur Ventures1 shared
Not Boring Capital1 shared
Lead Edge Capital1 shared
Venrock1 shared
Atlas Venture1 shared
New Enterprise Associates1 shared
Intel Capital1 shared
Catalio Capital Management1 shared
Palo Santo1 shared
Last updated: 20 October 2026